ArticleScientific reports2025
Helicobacter pylori eradication and gastric cancer prevention in a pooled analysis of large-scale cohort studies in Japan.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Prevention of Gastric Cancer.Medicina (Kaunas, Lithuania) · 2026Review
- Gastritis: Pathophysiology, Diagnosis, and Clinical Implications.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- A single-center culture-based study ofFrontiers in microbiology · 2026Article
- Review
- Evaluation of antimicrobial and antibiofilm activities of peptide Impatiens balsamina-M1 and Zinc oxide nanoparticles against Helicobacter pylori.Scientific reports · 2025Article
- Effect of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
- Forecasting age-standardized incidence rates of gastric cancer from 1990-2050 in Japan according to H. pylori prevalence and eradication scenarios.Journal of gastroenterology · 2025Article
- Investigating the relationship between Helicobacter pylori and intestinal Clostridioides difficile infection: evidence from a cross-sectional study.BMC gastroenterology · 2025Article
- Comparative insights intoFrontiers in microbiology · 2025Review
- Comparative analysis of gastric cancer risk attribution (1990-2021) and 2050 burden projection in China, Japan, and South Korea: an age-period-cohort modeling approach based on the Global Burden of Disease 2021 study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Helicobacter pylori (H. pylori) infection is an established cause of gastric cancer. Although H. pylori eradication is suggested to decrease gastric cancer risk, this has not been fully investigated in general populations. This analysis included 48,530 Japanese men and women aged 40-74 years from four cohort studies. At baseline, the participants provided a self-reported eradication history and serum anti-H. pylori IgG titers and the results of a pepsinogen (PG) test. We examined the association between eradication history and gastric cancer risk considering H. pylori positivity and PG testing using Cox proportional hazards regression models. From 2010 to 2018, 649 gastric cancer cases were diagnosed. Compared with those who were negative for both H. pylori and PG test as a reference, gastric cancer risk was 5.89 times higher (95%CI: 4.41-7.87) in those who were H. pylori-positive and/or PG test-positive and with no eradication at baseline. Gastric cancer risk among those who underwent eradication before baseline decreased after a temporal increase in risk following eradication (baseline to < 1y: HR 1.74, 95%CI 1.18-2.57; 1y to < 6y: HR 0.81, 95%CI 0.59-1.11; ≥ 6y: HR 0.44, 95%CI 0.28-0.68). In this large Japanese general population, H. pylori eradication was associated with a long-term reduction in gastric cancer incidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.